Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell vaccine (Cantonal Hospital of St. Gallen)
- Development stage
- Phase 2
- Lead developer
- Cantonal Hospital St. Gallen
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal
01
Overview
This is an autologous dendritic cell-based immunotherapy developed by the Cantonal Hospital of St. Gallen for the treatment of hormone-refractory prostate cancer. The vaccine is prepared by harvesting a patient's own dendritic cells and pulsing them with a cocktail of four HLA-A*0201-restricted peptides derived from prostate-specific antigens: prostate stem cell antigen (PSCA), prostatic acid phosphatase (PAP), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA). When administered intradermally, these mature, antigen-loaded dendritic cells present the peptides to the immune system to stimulate a T-cell-mediated response against prostate cancer cells expressing these markers.
- Other names
- Antigen-Loaded DC Vaccinationpeptide pulsed autologous dendritic cells
Beyond the preview
Go deeper on autologous dendritic cell vaccine (Cantonal Hospital of St. Gallen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell vaccine (Cantonal Hospital of St. Gallen).